168 related articles for article (PubMed ID: 36401664)
1. Alterations in the gut microbiome in patients with esophageal carcinoma in response to esophagectomy and neoadjuvant treatment.
Hasuda H; Ikeda T; Makizaki Y; Yokota H; Tanaka Y; Ohno H; Shimokawa M; Matsuoka H; Kimura Y; Oki E; Yoshizumi T
Surg Today; 2023 Jun; 53(6):663-674. PubMed ID: 36401664
[TBL] [Abstract][Full Text] [Related]
2. Minimal invasive versus open esophagectomy for patients with esophageal squamous cell carcinoma after neoadjuvant treatments.
Chen D; Wang W; Mo J; Ren Q; Miao H; Chen Y; Wen Z
BMC Cancer; 2021 Feb; 21(1):145. PubMed ID: 33563244
[TBL] [Abstract][Full Text] [Related]
3. Alterations in gut microbiota of esophageal squamous cell carcinoma patients.
Cheung MK; Yue GGL; Lauw S; Li CSY; Yung MY; Ng SC; Yip HC; Kwan HS; Chiu PWY; Lau CBS
J Gastroenterol Hepatol; 2022 Oct; 37(10):1919-1927. PubMed ID: 35816164
[TBL] [Abstract][Full Text] [Related]
4. Crosstalk between the gut microbiome and clinical response in locally advanced thoracic esophageal squamous cell carcinoma during neoadjuvant camrelizumab and chemotherapy.
Xu L; Qi Y; Jiang Y; Ji Y; Zhao Q; Wu J; Lu W; Wang Y; Chen Q; Wang C
Ann Transl Med; 2022 Mar; 10(6):325. PubMed ID: 35433940
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy followed by minimally invasive esophagectomy is safe and feasible for treatment of esophageal squamous cell carcinoma.
Ma S; Yan T; Liu D; Wang K; Wang J; Song J; Wang T; He W; Bai J; Jin L; Chen X
Thorac Cancer; 2018 Feb; 9(2):310-315. PubMed ID: 29319236
[TBL] [Abstract][Full Text] [Related]
6. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
Gong L; Mao W; Chen Q; Jiang Y; Fan Y
Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
[TBL] [Abstract][Full Text] [Related]
7. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
[TBL] [Abstract][Full Text] [Related]
8. Gut microbiome can predict chemoradiotherapy efficacy in patients with esophageal squamous cell carcinoma.
Sasaki T; Matsumoto Y; Murakami K; Endo S; Toyozumi T; Otsuka R; Kinoshita K; Hu J; Iida S; Morishita H; Nishioka Y; Nakano A; Uesato M; Matsubara H
Esophagus; 2023 Oct; 20(4):691-703. PubMed ID: 37086309
[TBL] [Abstract][Full Text] [Related]
9. Minimally Invasive Esophagectomy with Thoracic Duct Resection Post Neoadjuvant Chemoradiotherapy for Carcinoma Esophagus-Impact on Lymph Node Yield and Hemodynamic Parameters.
Anand S; Kalayarasan R; Chandrasekar S; Gnanasekaran S; Pottakkat B
J Gastrointest Cancer; 2019 Jun; 50(2):230-235. PubMed ID: 29344808
[TBL] [Abstract][Full Text] [Related]
10. Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma.
Akiyama Y; Iwaya T; Endo F; Chiba T; Takahara T; Otsuka K; Nitta H; Koeda K; Mizuno M; Kimura Y; Sasaki A
Surg Endosc; 2018 Jan; 32(1):391-399. PubMed ID: 28664431
[TBL] [Abstract][Full Text] [Related]
11. PATHOLOGIC COMPLETE RESPONSE (YPT0 YPN0) AFTER CHEMOTHERAPY AND RADIOTHERAPY NEOADJUVANT FOLLOWED BY ESOPHAGECTOMY IN THE SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS.
Andreollo NA; Beraldo GC; Alves IPF; Tercioti-Junior V; Ferrer JAP; Coelho-Neto JS; Lopes LR
Arq Bras Cir Dig; 2018 Dec; 31(4):e1405. PubMed ID: 30539980
[TBL] [Abstract][Full Text] [Related]
12. Feasibility study of adjuvant chemotherapy with S-1 after curative esophagectomy following neoadjuvant chemotherapy for esophageal cancer.
Hirahara N; Matsubara T; Kaji S; Hayashi H; Kawakami K; Sasaki Y; Takao S; Takao N; Hyakudomi R; Yamamoto T; Tajima Y
BMC Cancer; 2022 Jun; 22(1):718. PubMed ID: 35768866
[TBL] [Abstract][Full Text] [Related]
13. Removal of tumor thrombus from the azygos vein in an esophageal squamous cell carcinoma patient.
Lu Q; Shi B; Hong J; Chen H; Li C
J Cardiothorac Surg; 2020 Mar; 15(1):52. PubMed ID: 32228632
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients.
Chen CY; Li CC; Chien CR
World J Surg Oncol; 2018 Jul; 16(1):141. PubMed ID: 30007409
[TBL] [Abstract][Full Text] [Related]
15. Evaluating Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma.
Sun R; Tian L; Wei LJ
JAMA Surg; 2022 May; 157(5):458-459. PubMed ID: 35080625
[No Abstract] [Full Text] [Related]
16. Influence of Induction Therapy on Robot-Assisted McKeown Esophagectomy for Esophageal Squamous Cell Carcinoma.
Duan X; Gong L; Yue J; Shang X; Ma Z; Tang P; Chen C; Jiang H; Yu Z
Dig Surg; 2020; 37(6):463-471. PubMed ID: 32728007
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of plasma fibrinogen level as a predictive marker for postoperative recurrence of esophageal squamous cell carcinoma in patients receiving neoadjuvant treatment.
Matsuda S; Takeuchi H; Fukuda K; Nakamura R; Takahashi T; Wada N; Kawakubo H; Saikawa Y; Omori T; Kitagawa Y
Dis Esophagus; 2014; 27(7):654-61. PubMed ID: 23980622
[TBL] [Abstract][Full Text] [Related]
18. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
[TBL] [Abstract][Full Text] [Related]
20. Serum IgG level is a predicting factor for the response to neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma.
Nakaya S; Ogawa R; Hayakawa S; Fujihata S; Okubo T; Sagawa H; Tanaka T; Takahashi H; Matsuo Y; Takiguchi S
World J Surg Oncol; 2021 Jul; 19(1):217. PubMed ID: 34281546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
